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Accordingly, an alternative chromatic compound that
overcomes these disadvantages is preferred.

COMPOSITION OF, METHOD OF PRODUCING
AND METHOD OF USING A STABILIZED
FORMULATION FOR ASSAYING PEROXIDASE
ACTIVITY

One group of chromatic compounds found to over
come the disadvantages described above is of the benzi

dine type, particularly tetraalkybenzidine or salts
thereof. The most successfully used compound of this
type is 3,3',5,5’-tetramethylbenzidine (TMB). This com
pound was synthesized in 1974 and found to have suffi
cient color sensitivity for use in peroxidase assays and in

TECHNICAL FIELD

The present invention relates generally to assaying
peroxidase activity and more particularly to a stabilized
formulation for use in such activity and a method of

addition has been shown to desirably be noncarcino

genic (Garner et al., Cancer Letters 1, 39-42 (1975);

making the formulation.

Garner et al., J. Forensic Sci. 21, 8l6—82l (1976)). These
qualities have popularized TMB to become the chro

BACKGROUND OF THE INVENTION
Many assay procedures utilize enzymes as catalysts
for analytical reactions. In particular, the enzyme per
oxidase is among the most commonly used in enzymatic
detection reactions.

matic compound of choice for use as a substrate for

peroxidase assay (Bos et a1 , J. Immunoassay 2, 187-204

(1981)).
While TMB provides many desirable qualities for use
as a chromatic compound, it has the disadvantage of

Peroxidases are widespread in nature, being found
particularly in a variety of plants. They appear to cata
lyze the same reaction, but differ markedly in physico
chemical and kinetic properties. Three main types of

low ‘stability. Hydrogen peroxide has also long been
known to be relatively unstable in solution. Accord
ingly, early use of the reagents as a combined substrate

involved mixing them together at the time of the proce
dure and then introducing the combination to the test
medium. Such a procedure is relatively inconvenient

peroxidases have been identi?ed: acidic peroxidases
with very high carbohydrate content; neutral or slightly
basic peroxidases of medium sugar content; and very
basic peroxidases of low sugar content. Among these

and has been known to lead to inadvertent mixing errors

that directly result in incorrect test results.
Artisans have tried in the past to produce a combined
chromatic compound/peroxide substrate in advance of
the test procedure but the same low stability of the
substrate mixture was found. More particularly, when

peroxidases, the C isozyrne of horseradish peroxidase is
most commonly encountered in biotechnology.
Horseradish peroxidase is popularly used in labeling

haptens, antibodies, protein A/G, avidin/streptavidin
and DNA for enzyme immunoassay, immunocytochem
istry, immunoblot and DNA detection. Detection of
enzyme activity in the assay procedures takes advan
tage of the reactive cooperation between the enzyme
and a highly sensitive color-forming agent or chromatic
compound. The chromatic compound is a hydrogen
donor that changes color due to the loss of hydrogen

the TMB and H202 cannot coexist as a substrate formu

lation for extended periods of time. This is because of
the spontaneous evolution of color occurring due to the

decomposition of the peroxide to give oxygen radicals,
that attract hydrogen atoms from the chromatic com
pound. This occurs even in the absence of a catalyst
such as peroxidase. Thus the substrate solution becomes

atoms. The dehydrogenation occurs in the presence of

useless in a relatively short time period.
Attempts have been made to find a stabilizing agent
(H202). It is this oxidation reaction that is catalyzed by 40 that prevents the substrate solution containing both a
the peroxidase. Since a colored product results from the
chromatic compound and peroxide from deteriorating
reaction catalyzed by the enzyme, the peroxidase activ
when prepared and stored in a single container. One
ity is determined from the intensity of the color gener
such attempt is disclosed in U.S. Pat. No. 4,891,314 to
ated.
Pauly et al. The stabilizing agent utilized in the Pauly
Thus, in a typical assay protocol, the peroxidase is 45 formulation is penicillin. While the formulation includ

an oxidizing agent, typically hydrogen peroxide

?rst introduced to the test medium. Then the chromatic
compound and H202 are mixed to form a colorless
substrate that is added to the medium to test for the
enzyme. The chromatic compound as substrate under

ing the penicillin showed improvement over the prior
art by providing some stabilization of the substrate for
mulation, it is not without its drawbacks and limitations.
More particularly, it is disclosed that the addition of

goes an oxidation reaction when catalyzed by peroxi 50 penicillin provides only a relatively limited increase in
dase in the presence of H202. A colored product results
stability for one to several weeks. It has also been found
from the removal of hydrogen from the chromatic com
that color sensitivity can be improved over the formula

pound. The colored product is easily measured by spec

tion using penicillin as the stabilizing agent.

trophotometry.

Thus a need is identi?ed to find a formulation for use

Many different types of chromatic compounds have
been used in peroxidase assay procedures. When choos

as a substrate for assaying peroxidase activity that con
tains a chromatic compound, peroxide and a stabilizing

ing a chromatic compound to be used in combination
with H201 as a peroxidase substrate, it is desired that

agent that provides increased stabilization and color
sensitivity. The present invention is shown to satisfy
that need.

there be a high rate of oxidation and thus a high rate of

color conversion. It is further desired that the product 60
have a stable color for easy spectrophotometric mea

SUMMARY OF THE INVENTION

surement. Examples of known chromatic compounds

Accordingly, it is a primary object of the present

suitable as hydrogen donors are o-dianisidine, guaiacol,

invention to provide a formulation for use as a substrate

S-arninosalicylic acid, 2,2'-azino-di-(3-ethyl-benzthiazo
line-6-sulfonate) (ABTS), o-phenylenediarnine (OPD)
and l,2-benzenediamine. These chromatic compounds
have certain disadvantages such as high basal oxidation
or poor stability of oxidized product or are mutagenic.

for assaying peroxidase activity that overcomes the
65 drawbacks and disadvantages of the prior art.

Another object of the present invention is to provide
a stabilized chromatic compound/peroxide formulation
for use as a substrate in assaying peroxidase activity that
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saves storage space by eliminating the need to maintain
separate containers of the individual reagents.
It is a further object of the present invention to pro
vide a chromatic compound/peroxide formulation for
use as a substrate in assaying peroxidase activity which
eliminates the need to mix the individual reagents at the
time of the test procedure and hence is more convenient
to use.

It is an additional object of the present invention to

provide a combined chromatic compound/peroxide
formulation for use in assaying peroxidase activity that

exhibits signi?cantly improved stability.
Another object of the present invention is to provide
a chromatic compound/peroxide formulation for use as

a substrate in assaying peroxidase activity that provides
enhanced detection sensitivity.

'

It is still a further object of the present invention is to

provide a chromatic compound/peroxide formulation
for use as a substrate in assaying peroxidase activity that

provides longer storage life than is available with prior
art formulations.

Other objects and advantages of the present invention

4

ture, are then thoroughly mixed together and stored in
an amber bottle at 4° C. in a dark place. The stabilized
formulation is ready to be conveniently utilized in a
peroxidase enzyme assay or enzyme immunoassay as

desired.
In a typical enzyme linked irnmunosorbent assay
(ELISA) test, a test sample to be checked ‘for the pres
ence of an antigen is introduced into an assaying envi
ronment or microwell containing antibodies specific for

the antigen along with antigen-peroxidase conjugate. If
the antigen is present in good concentration, it prevents
the antigen-peroxidase conjugate from binding to the
immobilized antibodies. However, if the antigen is pres
ent in low concentration, a greater amount of antigen
peroxidase conjugate is bound to the antibodies.
After a period of incubation, the microwell is washed
to remove any unbound antigen-peroxidase conjugate.

The colorless substrate formulation containing H102
and the chromatic compound is then added. The test

20 sample and formulation is then examined for the pres

ence or absence of color. Any antigen-peroxidase con

jugate bound to the antibodies in the test sample cata
will become apparent as the description thereof pro
lyzes the oxidation between H202 and the chromatic
'ceeds.
compound, resulting in the evolution of a colored prod
In satisfaction of the foregoing objects and advan 25 uct. The optical density of the colored product is mea
tages, there is provided by this invention a formulation
sured and compared to calibration tables to determine
for use as a substrate in assaying peroxidase activity
the
extent of peroxidase activity.
including a chromatic compound, a peroxide and a
stabilizing agent selected from a group including baci
DETAILED DESCRIPTION OF THE
tracin, its precursor, bacitracin components derived by
INVENTION
hydrolysis or any mixtures thereof. The use of bacitra
As indicated above, this invention relates to an inno
cin or its family as a stabilizing agent allows the sub
vative
and novel stabilized substrate formulation for use
strate solution to be prepared in advance of the assay

in assaying peroxidase activity. The resulting formula
procedures and stored for months without deterioration
35 tion may be stored in solution over long periods of time
of the reactive components.
and provides enhanced color sensitivity for excellent
The chromatic compound used in the inventive sub
results in the assay procedure.
strate formulation is selected from a group consisting of
The formulation is formed of a mixture of two solu
tetraalkylbenzidine, salts of tetraalkylbenzidine or any
tions.
The ?rst solution includes a chromatic com
mixtures thereof. The preferred substrate is 3,3',5,5’-tet
pound. Preferably, the chromatic compound is selected
ramethylbenzidine (TMB).
from a group consisting of tetraalkylbenzidine, salts of
The TMB is dissolved in a water-miscible organic

solvent to form a ?rst solution. Examples of solvents
suitable for use include dimethyl sulfoxide (DMSO),
dimethyl formamide, dioxane or tetrahydrofuran. The
TMB is most commonly dissolved in DMSO.
A second solution including the stabilizing agent is
prepared to mix with the ?rst solution to form the ?nal
formulation. An aqueous buffer solution is prepared
utilizing an acidic buffer substance. Such buffers as

tetraalkylbenzidine or any mixtures thereof. The most

popular chromatic compound is 3,3',5,5’-tetramethyl
benzidine (TMB). This compound can be obtained from
Aldrich Chemical Company or Sigma Chemical Com
pany.

The TMB is dissolved in a water-miscible organic
solvent. While such solvents as dimethyl formamide,
dioxane or tetrahydrofuran may be employed, the pre

citrate, acetate and phosphate may be employed as the 50 ferred solvent is dimethyl sulfoxide (DMSO). The TMB
is typically dissolved in DMSO at a concentration of
buffer substance. The buffer is utilized to adjust the pH
between 25 mM and 33 mM.
of the ?nal formulation to the optimum level for storage
The second solution includes a stabilizing agent and
and use.
an acidic buffer substance. The buffer substance may be,
The stabilizing agent in the form of a bacitracin com
pound is added to the aqueous buffer solution. It is 55 for example, chosen from a group consisting of citrate,
acetate and phosphate or mixtures thereof. Preferably
commonly known in the art that bacitracin is a peptide
citrate is used to adjust the pH. When the ?nal formula
chain including a series of amino acids. A bacitracin
tion is prepared, the pH generally falls within a range
precursor, i.e. a longer peptide chain including the basic
between 2.5 and 6.0, and most desirably, between 3.0
bacitracin constituents, may also be utilized. The use of
bacitracin components, i.e. The parent bacitracin pep 60 and 4.0.
The stabilizing agent used in the invention substrate
tide chain broken down into smaller peptide chains by
formulation is bacitracin, such as may be obtained also
hydrolysis, is also suggested.
from Aldrich Chemical Company or Sigma Chemical
A peroxide either in liquid or solid form is added to
Company. Since bacitracin is a peptide chain including
the aqueous buffer solution including the stabilizing
agent. Typically, hydrogen peroxide or, alternatively, 65 a series of amino acids, a longer peptide chain including
the basic bacitracin constituents (i.e. a bacitracin pre
urea hydrogen peroxide is used as the liquid or solid
peroxide, respectively. The TMB solution and the
cursor) may be used. Further, bacitracin components,
formed by the breakdown of the parent bacitracin struc
peroxide/bacitracin solution, made at room tempera
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after sixty days of storage.
'
In summary, numerous bene?ts have been described

A peroxide for use as an oxidizing agent in the assay

which result from employing the concept of the present

reaction is added to the second solution. A liquid perox
ide in the form of hydrogen peroxide or a solid perox
ide, such as urea hydrogen peroxide, may be used.

invention. A novel stabilized formulation for use as a

substrate in assaying peroxidase activity is disclosed.
This formulation includes a chromatic compound such
as TMB in solution with H202 and a stabilizing agent

The two solutions are prepared at room temperature

and mixed together thoroughly. The ratio between the
organic solvent and the aqueous buffer solution includ

ing the peroxide and stabilizing agent is preferably in

from the bacitracin family. The formulation provides
0 for longer storage life for the combination than seen in

the prior art. The formulation also enhances the detec
tion sensitivity during the assay procedure.
.
The invention has been described herein with refer

the range between 1:99 and 35:65. The formulation is
stored in an amber bottle at 4° C. and has been shown to

remain stable for a period of several months. The stabi

ence to certain preferred embodiments. However, as

lized formulation is ready for use at any time an assay is
conducted. The ?nal concentration ranges of the com
ponents of the formulation are as follows:

obvious variations thereon will become apparent to
those skilled in the art, the invention is not to be consid
ered as limited thereto.
I claim:
1. A formulation for the detection and determination

Chromatic compound: 1.0 mM-1.75 mM
Stabilizing agent: 0.5 mM-2.0 mM
Peroxide: 2 mM-lO mM
20

Buffer: 25 mM-lOO mM

6

indicating enzymatic and non-enzymatic activity even

ture into smaller peptide chains and components by
hydrolysis, may also be used.

of peroxidase activity, comprising:
a chromatic compound;

The following example is presented to illustrate the

a peroxide;

invention but it is not to be considered as limited

>

a water-miscible organic solvent;

thereto.

Citric acid monohydrate (3.60 gm) and trisodium

an aqueous buffer solution; and
a stabilizing agent selected from a group consisting of
bacitracin, bacitracin precursors, bacitracin com

citrate dihydrate (1.838 gm) was dissolved in 950 ml of
double-distilled water. Bacitracin (1.422 gm) was then
added with stirring until it dissolved. Urea hydrogen
peroxide (0.564 gm) was added to the above with con

thereof.
2. The formulation set forth in claim 1 wherein said
chromatic compound is selected from a group consist

EXAMPLE

25

tinuous stirring. 3,3',5,5'-Tetramethylbenzidine (300
mg) was ?rst completely dissolved in 50 ml of dimethyl
sulfoxide before adding to the above solution. After
thorough mixing in an amber bottle the solution was
ready for use or storage at 4° C. The ?nal concentra
tions of each of the above components was: bacitracin,

ponents derived by hydrolysis and mixtures

ing of tetraalkylbenzidine, salts of tetraalkylbenzidine
and mixtures thereof.
3. The formulation set forth in claim 1 wherein said

chromatic compound is 3,3',5,5'-tetramethylbenzidine.
4. The formulation set forth in claim 1 wherein said
water-miscible organic solvent is selected from a group

consisting of dioxane, tetrahydrofuran, dimethyl sulfox

1.0 mM; urea hydrogen peroxide, 6 mM; TMB, 1.25
mM; DMSO, 5%; citrate, 25 mM and the ?nal pH was

ide, dimethyl formamide and mixtures thereof.

stabilityat various temperatures. Table I indicates the

ing of citrate, acetate, phosphate and mixtures thereof.

5. The formulation set forth in claim 1 wherein said
3.4.
The above substrate solution was examined for its 40 buffer is an acidic buffer selected from a group consist

absorbance reading at 650 nm when the solution was
incubated at 4° C., 37° C. or 97° C. for the indicated

6. The formulation set forth in claim 1 wherein a ratio

between said organic solvent and said aqueous solution
is between 1:99 and 35:65 volume percent.

length of time and then 100 ul of the aliquots were
7. The formulation set forth in claim 1 wherein a ?nal
allowed to react with 100 pg of horseradish peroxidase 45
concentration
of said chromatic compound is between
(HRP) at room temperature for 10 min. The absorbance
1.0 mM and 1.75 mM.
reading was stabilized by adding 100 ul of 1 M phos
8. The formulation set forth in claim 1 wherein a final
phoric acid and determined at 450 nm.
concentration of said peroxide is between 2.0 mM and
TABLE l
50 10.0 mM.
EFFECT OF DIFFERENT TEMPERATURES
ON SUBSTRATE STABILITY
(Absorbance at 650 nm after
10 minutes incubation at room temperature)
zero time
30 days
60 days
4' C.

37' C

and 2.0 mM.
10. The formulation set forth in claim 1 wherein said
55 formulation has a pH between 2.5 and 6.0.
11. A method of assaying peroxidase activity in a test

— HRP

0.037

0.038

+I-IRP

1.251

1.230

1.212

zero time

5 days

10 days

0.037
1.230

0.040
1.191

0.045
1.173

introducing said test sample into an assaying environ

zero time

2 hours

4 hours

0.037
L470

0.041
1.405

0.046
1.005

exposing said test sample to said formulation;
incubating said test sample and formulation mixture;
and
examining said test sample and formulation mixture

—l-IRP
+HRP

0.040

9. The formulation set forth in claim 1 wherein a ?nal

concentration of stabilizing agent is between 0.5 mM

sample using the formulation of claim 1, comprising the
steps of:
ment;

97' C.

—HRP
+HRP

'
'

for the presence or absence of a colored product.
The absorbance values in Table 1 clearly show the 65
12. A process for the preparation of a formulation for
excellent color sensitivity of the substrate formulation.
the detection and determination of peroxidase activity,
With reference to the formulation sample stored at 4°
comprising the steps of:
C., there was a signi?cant distinction between readings

7
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forming a ?rst solution by dissolving a chromatic
compound in a water miscible organic solvent;
forming a second solution by preparing an aqueous

8

16. The process of claim 12, wherein said aqueous
buffer solution is formed using an acidic buffer.
17. The process of claim 16, wherein said acidic
buffer is selected from a group consisting of citrate,

acidic buffer solution and adding in any order a

acetate, phosphate and mixtures thereof.
18. The process of claim 12, wherein a ratio between
said ?rst solution and said second solution is between
1:99 and 35:65 volume percent.

stabilizing agent selected from a group consisting
of bacitracin, bacitracin precursors, bacitracin
components derived by hydrolysis and mixtures

thereof and a peroxide; and
mixing said ?rst and second solutions to form said
19. The process of claim 12, wherein a ?nal concen
formulation.
10 tration of said chromatic compound is between 1.0 mM
and 1.75 mM.
13. The process of claim 12, wherein said water-mis
cible organic solvent is selected from a group consisting
20. The process of claim 12, wherein a ?nal concen
tration of said stabilizing agent is between 0.5 mM and
of dioxane, tetrahydrofuran, dimethyl sulfoxide, di
methyl formamide and mixtures thereof.
2 mM.
14. The process of claim 12, wherein said chromatic 15
21. The process of claim 12, wherein a ?nal concen
tration of said peroxide is between 2.0'mM and 10.0
compound is selected from a group consisting of tet
raalkylbenzidine, salts of tctraalkylbenzidine, and mix
mM.
tures thereof.
22. The process as in claim 12, wherein said formula
tion has a pH of between 2.5 and 6.0.
15. The process of claim 12, wherein said chromatic

compound is 3,3’, 5,5’-tetramethylbenzidine.
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